Watson seeks to market generic Avodart

Watson Pharmaceuticals has confirmed that one of its units has filed an ANDA with the FDA seeking approval to market dutasteride capsules, 0.5 mg. The capsules are a generic version of GlaxoSmithKline's Avodart, which is indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. GSK has filed suit to block the generic challenge. Watson release

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.